Noncoding RNA Drug Target for Colon Cancer Discovered

06:03 EDT 17 May 2018 | Genetic Engineering News

Long noncoding RNAs (lncRNAs) are, as the name suggests, long transcripts of RNA that do not code for proteins, but have been found to regulate a wide range of cell functions. Scientists at Case Western Reserve School of Medicine have now discovered that one lncRNA, designated lincDUSP, may play a role in initiating colon cancer and promoting disease progression, and so represent a novel target for drug development. The team found that lincDUSP was overexpressed in nearly every human colon cancer sample examined. Laboratory tests then showed that the characteristic unrestricted growth of human tumor-derived colon cancer lines stopped when lincDUSP was deleted, and the cells began to replicate at normal rates. “Our work demonstrates that not only protein-coding genes but also noncoding genes contribute to colon cancer progression,” comments Ahmad Khalil, Ph.D., assistant professor of genetic and genome sciences at Case Western Reserve University School of ...

Original Article: Noncoding RNA Drug Target for Colon Cancer Discovered


More From BioPortfolio on "Noncoding RNA Drug Target for Colon Cancer Discovered"

Quick Search


Relevant Topics

Colorectal Cancer
Colon or Colorectal cancer is the growth of malignant polyps on the colon, bowel, anus and rectum. Growths in these locations can be benign, and removed by colonoscopy, but they have a risk of becoming malignant.  About 10 per cent of bowel cancer...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...